Related Experiment Video For Artificial Intelligence
Updated: Sep 9, 2025

Slicing and Culturing Pig Hearts under Physiological Conditions
Published on: March 20, 2020
Mixture of experts for multitask learning in cardiotoxicity assessment
Edoardo Luca Viganò1, Mateusz Iwan2, Erika Colombo2
1Laboratory of Environmental Toxicology and Chemistry, Department of Environmental Health Sciences, Instituto Di Ricerche Farmacologiche Mario Negri IRCSS, 20156, Milan, Italy. edoardo.vigano@marionegri.it.
Abstract:
In recent years, the integration of Artificial Intelligence and Machine Learning methods with biochemical and biomedical research has revolutionized the field of toxicology, significantly advancing our understanding of the toxicological effects of chemicals on biological systems. Cardiovascular diseases remain the leading global cause of death. The constant exposure to multiple chemicals with potential cardiotoxic effects, including environmental contaminants, pesticides, food additives, and drugs, can significantly contribute to these adverse health outcomes. Traditional methods for assessing chemical hazards and their impact on biological function heavily rely on experimental assays and animal studies, which are often time-consuming, resource-intensive, and limited in scalability. To overcome these limitations in silico methods have emerged as indispensable tools in toxicological research, reducing the need for traditional in vivo testing and conserving valuable resources in terms of time and cost. In this study, Artificial Intelligence methods are used as first-tier components within an Integrated Approach to Testing and Assessment. We explored the potential benefits of using Multitask Neural Networks, where multiple levels of cardiotoxicity information are combined to enhance model performance. Multitask learning, based on specific architectures such as Mixture of Experts (MoE), showed promising results and surpasses the performance of single-task baseline models. When predicting a holdout set, multitask model achieved high performance on twelve different endpoints related to cardiotoxicity defined by Adverse Outcome Pathways Network. The best developed model achieved a balanced accuracy of 78%, a sensitivity of 80%, and a specificity of 76% across all endpoints in the holdout set. SCIENTIFIC CONTRIBUTION: An advanced multitask model was developed to predict cardiotoxicity mechanisms induced by small molecules. The model demonstrates broad mechanistic coverage and achieves performance comparable to, or exceeding, state-of-the-art methods. These results suggest that the model could serve as a valuable first-tier component in advanced New Approach Methodologies for prioritizing chemicals for further testing.
More Related Videos
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
Related Concept Videos
Multicompartment Models: Overview
These models offer a more comprehensive representation of drug behavior in the body than one-compartment models. They accommodate the complexity of drug distribution,...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Cardiomyopathy V: Interprofessional Care
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Cardiopulmonary Resuscitation IV: Pharmacological Management